department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

valemetostat · pharmadog

pharmadog
drugs
valemetostat

drug

patient view →

valemetostat

Phase 2updated 2mo ago

by Daiichi Sankyo Co Ltd

Phase 2

community read0 votes

indications

indications

NSCLC

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

generic

valemetostat [INN]

indication

Non-Small Cell Lung Cancer

phase

phase_2

Data sources

ClinicalTrials.gov

last refreshed 57m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying valemetostat

phase1A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancerrecruitingn=24
phase1A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)recruitingn=60
phase2Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.recruitingn=900
phase2A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphomarecruitingn=60
phase2A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)active not recruitingn=438
phase2Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphomaactive not recruitingn=141
phase1A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumorsrecruitingn=210
phase1Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Canceractive not recruitingn=17

more trials →